BRPI0607533A2 - derivado de ftalazinona, composição farmacêutica, inibidor de fosfodiesterase do tipo 4,supressor da produção de tnf-alfa, agente preventivo ou terapêutico, preparado externo, bem como uso do referido derivado - Google Patents
derivado de ftalazinona, composição farmacêutica, inibidor de fosfodiesterase do tipo 4,supressor da produção de tnf-alfa, agente preventivo ou terapêutico, preparado externo, bem como uso do referido derivadoInfo
- Publication number
- BRPI0607533A2 BRPI0607533A2 BRPI0607533-9A BRPI0607533A BRPI0607533A2 BR PI0607533 A2 BRPI0607533 A2 BR PI0607533A2 BR PI0607533 A BRPI0607533 A BR PI0607533A BR PI0607533 A2 BRPI0607533 A2 BR PI0607533A2
- Authority
- BR
- Brazil
- Prior art keywords
- derivative
- tnf
- preventive
- pharmaceutical composition
- therapeutic agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Abstract
DERIVADO DE FTALAZINONA, COMPOSIçãO FARMACêUTICA, INIBIDOR DE FOSFODIESTERASE DO TIPO 4, SUPRESSOR DA PRODUçãO DE TNF-ALFA, AGENTE PREVENTIVO OU TERAPêUTICO, PREPARADO EXTERNO, BEM COMO USO DO REFERIDO DERIVADO. A presente invenção refere-se a um novo composto tendo uma excelente atividade inibitória de PDE4 e atividade de supressão da produção de TNF-<244> e também proporciona um agente preventivo e terapêutico para dermatite atópica ou similar. A presente invenção inclui um novo derivado de ifalazinona da presente fórmula estrutural geral [1] a seguir ou um sal farmaceuticamente aceitável do mesmo e uma composição farmacêutica compreendendo o mesmo como um ingrediente ativo. Na fórmula estrutural [1], a estrutura parcial de ligação em ponte na posição 6 e na posição 7 a seguir representa uma ligação simples ou uma ligação dupla: R¹ e R² são os mesmos ou diferentes e cada um representa alquila ou similar, Y representa fenileno ou similar, Z representa alquileno ou similar, R³ representa um grupo amino cíclico saturado ou insaturado monoa tricíclico ou similar, R³¹ e R³² representa alquila ou similar.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005124247 | 2005-04-21 | ||
PCT/JP2006/308460 WO2006115221A1 (ja) | 2005-04-21 | 2006-04-21 | フタラジノン誘導体及びその医薬 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0607533A2 true BRPI0607533A2 (pt) | 2009-09-15 |
Family
ID=37214836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0607533-9A BRPI0607533A2 (pt) | 2005-04-21 | 2006-04-21 | derivado de ftalazinona, composição farmacêutica, inibidor de fosfodiesterase do tipo 4,supressor da produção de tnf-alfa, agente preventivo ou terapêutico, preparado externo, bem como uso do referido derivado |
Country Status (10)
Country | Link |
---|---|
US (1) | US20090042879A1 (pt) |
EP (1) | EP1873147A4 (pt) |
JP (1) | JPWO2006115221A1 (pt) |
KR (1) | KR20080000642A (pt) |
CN (1) | CN101163681A (pt) |
AU (1) | AU2006240730A1 (pt) |
BR (1) | BRPI0607533A2 (pt) |
CA (1) | CA2605383A1 (pt) |
RU (1) | RU2007143049A (pt) |
WO (1) | WO2006115221A1 (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1824847A2 (en) | 2004-12-17 | 2007-08-29 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
MX2008016519A (es) | 2006-06-22 | 2009-01-30 | Anadys Pharmaceuticals Inc | Compuestos de pirro[1,2,-b]piridazinona. |
US8153664B2 (en) * | 2006-10-04 | 2012-04-10 | Schering Corporation | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
CL2007003587A1 (es) * | 2006-12-12 | 2008-07-04 | Anadys Pharmaceuticals Inc | Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c. |
US20100184770A1 (en) * | 2006-12-20 | 2010-07-22 | Glaxo Group Limited | Compounds |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
US7834009B2 (en) | 2007-08-27 | 2010-11-16 | Anadys Pharmaceuticals, Inc. | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds |
WO2009152166A1 (en) | 2008-06-10 | 2009-12-17 | Anadys Pharmaceuticals, Inc. | [1,2,4]thiadiazine 1,1-dioxide compounds |
TW201026675A (en) | 2008-10-09 | 2010-07-16 | Anadys Pharmaceuticals Inc | 5,6-dihydro-1H-pyridin-2-one compounds |
WO2011056647A1 (en) | 2009-10-28 | 2011-05-12 | Anadys Pharmaceuticals, Inc. | Deuterated 5,6-dihydro-1h-pyridin-2-one compounds |
CN102964340B (zh) * | 2012-12-12 | 2015-10-07 | 中国药科大学 | 一类治疗阿尔茨海默病的选择性多巴胺d1受体激动剂 |
KR101708412B1 (ko) | 2013-10-21 | 2017-03-09 | 에이피시스템 주식회사 | 열처리 장치 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103718A (en) * | 1997-01-15 | 2000-08-15 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinones |
EP1228046B1 (en) * | 1999-10-25 | 2007-09-26 | Nycomed GmbH | Phthalazinone derivatives as pde 4 inhibitors |
EP1385838A1 (en) * | 2001-04-25 | 2004-02-04 | ALTANA Pharma AG | Piperazino-derivatives and their use as pde4 inhibitor |
IL157908A0 (en) * | 2001-04-25 | 2004-03-28 | Altana Pharma Ag | Phthalazinone derivatives and pharmaceutical compositions containing the same |
US20100184770A1 (en) * | 2006-12-20 | 2010-07-22 | Glaxo Group Limited | Compounds |
EP2518063B1 (en) * | 2006-12-21 | 2017-02-01 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
JP2011500537A (ja) * | 2007-10-11 | 2011-01-06 | グラクソ グループ リミテッド | H1受容体アンタゴニストとしてのフタラジンおよびピリド[3,4−d]ピリダジン化合物 |
UY31603A1 (es) * | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona |
-
2006
- 2006-04-21 KR KR1020077025818A patent/KR20080000642A/ko not_active Application Discontinuation
- 2006-04-21 EP EP06732218A patent/EP1873147A4/en not_active Withdrawn
- 2006-04-21 CA CA002605383A patent/CA2605383A1/en not_active Abandoned
- 2006-04-21 WO PCT/JP2006/308460 patent/WO2006115221A1/ja active Application Filing
- 2006-04-21 RU RU2007143049/04A patent/RU2007143049A/ru not_active Application Discontinuation
- 2006-04-21 JP JP2007514691A patent/JPWO2006115221A1/ja active Pending
- 2006-04-21 AU AU2006240730A patent/AU2006240730A1/en not_active Abandoned
- 2006-04-21 BR BRPI0607533-9A patent/BRPI0607533A2/pt not_active IP Right Cessation
- 2006-04-21 US US11/912,179 patent/US20090042879A1/en not_active Abandoned
- 2006-04-21 CN CNA200680013390XA patent/CN101163681A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2006240730A1 (en) | 2006-11-02 |
EP1873147A4 (en) | 2010-01-06 |
JPWO2006115221A1 (ja) | 2008-12-18 |
US20090042879A1 (en) | 2009-02-12 |
CA2605383A1 (en) | 2006-11-02 |
RU2007143049A (ru) | 2009-05-27 |
KR20080000642A (ko) | 2008-01-02 |
CN101163681A (zh) | 2008-04-16 |
WO2006115221A1 (ja) | 2006-11-02 |
EP1873147A1 (en) | 2008-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0607533A2 (pt) | derivado de ftalazinona, composição farmacêutica, inibidor de fosfodiesterase do tipo 4,supressor da produção de tnf-alfa, agente preventivo ou terapêutico, preparado externo, bem como uso do referido derivado | |
CO6220955A2 (es) | Una composicion farmaceutica que contiene (a) n1-(5-cloropiridin-2-il)-n2-((1s,2r,4s)-4-[dimetilamino)carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino} coclohexil)etanodiamida | |
BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
BRPI0616799B8 (pt) | derivado de piridina e derivado de pirimidina, composições farmacêuticas, usos, inibidores de angiogênese, contra receptor de fator de crescimento de hepatócito e contra metástase de câncer, e agente antitumor | |
CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
MY170326A (en) | Imidazo [1,2-b] pyridazine derivativea as kinase inhibitors | |
CU20110217A7 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
AR057915A1 (es) | Compuesto con estructura de cinamida de dos ciclos con actividad inhibitoria de la produccion de abeta40 y abeta42, un agente farmaceutico que lo comprende y el uso de este en el tratamiento de enfermedades mentales y neurodegenerativas. | |
AR068045A1 (es) | Derivados de catecolamina y prodrogas de los mismos | |
BR112014001468A2 (pt) | compostos de tetra-hidropirido-piridina e tetra-hidropirido-pirimidina e uso dos mesmos como modulares do receptor c5a | |
BRPI1009333B8 (pt) | compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica | |
BRPI0519287A2 (pt) | derivados de amida | |
BRPI0606817A2 (pt) | derivados de piridazina e seu uso como agentes terapêuticos | |
TN2010000026A1 (fr) | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met | |
AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
BR112015019369A2 (pt) | derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra) | |
ECSP088457A (es) | Compuestos de benzamida útiles como inhibidores de la histona deacetilasa | |
BR112013026361A2 (pt) | derivados de glicosídeo e usos dos mesmos | |
BRPI0418074B8 (pt) | derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos | |
BRPI0408189A (pt) | 8'-piridinil-dihidroespiro-[cicloalquil]-pirimido[1,2-a]p irimidin-6-ona substituìda e derivados de 8'-pirimidinil-dihidroespiro-[cicloalquil]-pirimido[1,2- a]pirimidin-6-ona e seus usos contra doenças neurodegenerativas | |
BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
NZ736015A (en) | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same | |
MX2020003993A (es) | Derivados de bencimidazol y sus usos. | |
BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
BR112015022385A2 (pt) | droga para uma doença respiratória |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2161 DE 05/06/2012. |